Neurotech International Ltd. · ASX:NTI
Neurotech International — South-West Connect ASX Showcase 2022
17 slides from Neurotech International's conference presentation, Oct 19, 2022
Slide 1: Neurotech to Present at Upcoming South-West Connect ASX Showcase
ASX Announcement 19 October 2022 Neurotech to Present at Upcoming South-West Connect ASX Showcase For personal use only Neurotech International Limited (ASX: NTI) (“Neurotech” or “the Company”), a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological d
Slide 2: Improving Lives - South-West Connect ASX Showcase
For personal use only Improving Lives South-West Connect Dr Tom Duthy Executive Director ASX Showcase 21 October 2022
Slide 3: Disclaimer
Disclaimer For personal use only IMPORTANT INFORMATION Purpose of presentation: This presentation (including this document, any related video or oral These events are, as at the date of this presentation, expected to take place, but there cannot be any presentation, any question and answer session a
Slide 4: Neurotech is a clinical-stage biopharmaceutical development company
Neurotech is a clinical-stage biopharmaceutical development For personal use only company focused predominately on paediatric neurological disorders Novel oral NTI164 exclusive worldwide PCT patent biopharmaceutical licence for neurological applications lodged cannabinoid platform disorders (NTI164)
Slide 5: Corporate / Capital Summary
Corporate / Capital Summary For personal use only $0.105 $75.1M ~$1.9M ~1,600 Share price (as at 12 October 2022) Market Cash at bank* No. of shareholders capitalisation 716.7M 124.1M^ ~$2.6M 57% Share on issue Options/rights R&D Investment Top 20 Holders in FY22 *as at 30 June 2022 ^Options are com
Slide 6: Neurotech Four Core Strategies
Neurotech Four Core Strategies For personal use only Focus On Rare Focus on Paediatric Patients Neurological Disorders with Neuroinflammation Focus on Partnering with Focus On Drug Product Key Opinion Leaders / Development Clinicians 5
Slide 7: Strategic Focus Offers Significant Value Upside
Strategic Focus Offers Significant Value Upside For personal use only • Often overlooked by big pharma • Can be unencumbered drug therapy markets (no standard of care, no approved treatments) Focus on Paediatric Patients • Lack of clinical trials that may compete for patients • Ability to leverage s
Slide 8: Rapid Progress from Lab to Clinic Drives Strategy
Rapid Progress from Lab to Clinic Drives Strategy For personal use only 2020 Extraction of Drug Product (NTI164) & Pre-Clinical Data 2021 • Reduction in brain cell inflammation (up to Manufacture Scale-Up & 60%) Analytical Methods Established 2022 Phase I/II Clinical Trial (Safety) • Increase in ove
Slide 9: Phase I/II Clinical Results: Autism Spectrum Disorder (ASD)
Phase I/II Clinical Results: Autism Spectrum Disorder (ASD) For personal use only “The goals of treatment for ASD are to improve core deficits in social communication and social interactions and minimize the impact of restricted behaviours, with an overarching goal to help children develop greater f
Slide 10: Autism Spectrum Disorder (ASD)
Autism Spectrum Disorder (ASD) For personal use only PREVALENCE OF ASD TREATMENT MARKET SIZE ~1 in 44 children 2 in the US1 US$1.85b RISPERIDONE Approved 2006 (irritability label claim) Market Current Treatment Clinical Trial ASD is a serious Huge unmet medical Initial Focus of NTI164 – A full spect
Slide 11: NTI164 ASD Phase I/II - Trial Design
NTI164 ASD Phase I/II - Trial Design For personal use only The Program First in human Phase I/II ASD paediatric study (S8) Commenced in May 2021 at Monash Children’s Hospital led by A/Prof. Michael Fahey Open label – single group 14 patients from 8 to 17yo, Level II and III Autism Spectrum Disorder
Slide 12: NTI164 ASD Phase I/II – Safety/Efficacy (28 Day Recap)
NTI164 ASD Phase I/II – Safety/Efficacy (28 Day Recap) For personal use only NTI164 was Safe No serious adverse events recorded Less Severe More Severe Across all doses 1 = normal (not at all) 2 = Borderline mentally ill 3 = Mildly ill 4 = Moderately ill 5 = Markedly ill 6 = Severely ill 7 = Among t
Slide 13: Rapid Pipeline Progression
Rapid Pipeline Progression For personal use only Pipeline (Pro-Forma 1 Jan 2023) Pipeline (2020/1) Pre-Clinical Phase I/II Phase II/III NTI164 Combination Therapies Prednisone, Diclofenac, Other NTI164 NTI164 NTI164 Combination Therapies Prednisone, Diclofenac, Other Cerebral Palsy ASD NTI164 Neuron
Slide 14: Key Month Milestones – NTI164
Key 12 Month Milestones – NTI164 For personal use only Q4 CY2022 1H CY2023 2H CY2023 • Results of ASD 20 week Phase I/II Clinical Trial • Commencement of Patient Recruitment • Results of PANDAS/PANS Phase I/II Clinical Trial PANDAS/PANS Phase I/II Clinical Trial • Human Research Ethics Committee (HR
Slide 15: Summary of Strategy
Summary of Strategy For personal use only Implementation Potential Group Strategy to Development Regulatory Levers Commercialisation Examples* Current 2016 2018/9 2021 Phase I/II PANDAS/PANS Pre-IND Feedback IND Orphan Drug Designation Priority Review Phase III Trials US$7.2 Billion Phase I/II acqui
Slide 16: Outlook
Outlook For personal use only • Focus on rare paediatric neurological disorders • Initial safety & efficacy of NTI164 now established in a predominant paediatric neurological disorder with strong neuroinflammatory effects (ASD) – 20 week data imminent • Accelerated clinical development via rapid & c
Slide 17: Contact Details
For personal use only Contact Details Dr Tom Duthy Executive Director [email protected] +61 402 493 727 *This presentation has been authorised by the Board of Neurotech International Limited www.neurotechinternational.com www.mentetech.com Neurotech International Limited (ASX: NTI) 16
Neurotech International — South-West Connect ASX Showcase 2022 on 6ix